OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
OKYO Pharma Limited is set to present its promising trial results for OK-101, a treatment for dry eye disease, at the International Tear Film & Ocular Surface Society Conference in Venice. The company is also advancing its Phase 2 trial for treating Neuropathic Corneal Pain, a market with no current FDA-approved therapies. These developments highlight OKYO’s commitment to addressing challenging ocular conditions and expanding its presence in the multi-billion-dollar eye care market.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.